BZL 101

Drug Profile

BZL 101

Alternative Names: Bezielle; BZL-101

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bionovo
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action Apoptosis stimulants; Glycolysis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Pancreatic cancer

Most Recent Events

  • 12 Mar 2012 No development reported - Preclinical for Pancreatic cancer in USA (PO)
  • 06 Feb 2012 Bionovo plans a phase II trial for Breast cancer in USA (NCT00907959)
  • 02 Nov 2010 Bionovo receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA) for controlled-release BZL 101 development in Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top